The U.K.'s National Institute for Health and Care Excellence, or NICE, did not recommend Roche Holding AG's Erivedge for use within the National Health Service.

The regulator said there was not enough evidence that demonstrated Erivedge, or vismodegib, was cost effective and better than existing therapies for metastatic basal cell carcinoma, a type of skin cancer.

As a result, the drug did not meet the criteria to be considered a life-extending end-of-life treatment.

Meanwhile, the regulator gave a conditional nod to Bayer AG's Stivarga for treating unresectable or metastatic gastrointestinal stromal tumors.

The drug will be available for patients with an eastern cooperative oncology group performance status of zero or one, meaning they must either be able to carry on all pre-disease performance without restriction or carry out work of a light or sedentary nature.